Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.
Read original at benzingaStocks · News reference
Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est
Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 11:31 AM
- Checked
- Aug 5, 2026, 11:31 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Bioventus (NASDAQ:BVS) with a Overweight and maintains $15 price target.
Read original at benzingaDeal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy
Major M&A deals include Visa buys BioCatch, Apollo Global nabs EasyJet, QVC emerges from Chapter 11 bankruptcy.
Read original at benzingaBioventus shares are trading higher after the company reported strong Q2 financial results and announced a review of strategic alternatives.
Read original at benzinga